Emily Field Analyst PerformanceDirector, Head of European Pharmaceuticals Equity Research at BarclaysEmily Field is a stock analyst at Barclays in the healthcare sector, covering 11 publicly traded companies. Over the past year, Emily Field has issued 21 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Emily Field's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Emily Field's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings24 Last 4 YearsBuy Recommendations45.83% 11 Buy RatingsCompanies Covered11 Unique Companies Ratings Distribution24RatingsDistribution of strong buy, buy, hold, and sell ratings by Emily Field.RatingPercentageCount Strong Buy4.2%1 ratings Buy41.7%10 ratings Hold45.8%11 ratings Sell8.3%2 ratingsOut of 24 total stock ratings issued by Emily Field at Barclays, the majority (45.8%) have been Hold recommendations, followed by 41.7% Buy, 8.3% Sell, and 4.2% Strong Buy.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNYSE54.5% of companies on NYSE6 companiesNASDAQ36.4% of companies on NASDAQ4 companiesOTCMKTS9.1% of companies on OTCMKTS1 companyEmily Field, an analyst at Barclays, currently covers 11 companies listed on NYSE, NASDAQ and OTCMKTS, with the majority traded on NYSE.Coverage FocusSector IconSectorPercentageHealthcare11 companies100.0%Emily Field of Barclays specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentagePHARMACEUTICALS6 companies54.5%BIOTECHNOLOGY5 companies45.5% Emily Field's Ratings History at Barclays Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsABBVAbbVie7/29/2026Boost Price Target$263.49$300.00Overweight$0.0000.00% ROIBIIBBiogen7/29/2026Boost Price Target$205.61$200.00Equal Weight$0.0000.00% ROIAMGNAmgen7/29/2026Boost Price Target$393.10$360.00Equal Weight$0.0000.00% ROIMRKMerck & Co., Inc.7/29/2026Boost Price Target$131.85$150.00Overweight$0.0000.00% ROIGILDGilead Sciences7/29/2026Lower Price Target$134.32$145.00Equal Weight$0.0000.00% ROILLYEli Lilly and Company5/4/2026Boost Price Target$968.06$1,400.00Overweight$0.0000.00% ROIGILDGilead Sciences2/20/2026Initiated Coverage$151.12$155.00Equal Weight$0.0000.00% ROIMRKMerck & Co., Inc.2/20/2026Initiated Coverage$121.83$140.00Overweight$0.0000.00% ROIAMGNAmgen2/20/2026Initiated Coverage$373.21$350.00Equal Weight$0.0000.00% ROIBIIBBiogen2/19/2026Initiated Coverage$192.08$185.00Equal Weight$0.0000.00% ROIPFEPfizer2/19/2026Initiated Coverage$26.87$25.00Underweight$0.0000.00% ROIABBVAbbVie2/19/2026Initiated Coverage$224.13$275.00Overweight$0.0000.00% ROIBMYBristol Myers Squibb2/19/2026Initiated Coverage$60.32$75.00Overweight$0.0000.00% ROILLYEli Lilly and Company2/19/2026Initiated Coverage$1,023.10$1,350.00Overweight$0.0000.00% ROIABBVAbbVie2/19/2026Initiated Coverage$224.94$275.00Overweight$0.0000.00% ROIAMGNAmgen2/19/2026Upgrade$374.75Hold$0.0000.00% ROIBIIBBiogen2/19/2026Upgrade$192.03Hold$0.0000.00% ROIBMYBristol Myers Squibb2/19/2026Initiated Coverage$60.66$75.00Overweight$0.0000.00% ROIGILDGilead Sciences2/19/2026Upgrade$151.40Hold$0.0000.00% ROILLYEli Lilly and Company2/19/2026Initiated Coverage$1,008.47$1,350.00Overweight$0.0000.00% ROIMRKMerck & Co., Inc.2/19/2026Upgrade$122.05Strong-Buy$0.0000.00% ROINVONovo Nordisk A/S7/30/2025Reiterated Rating$53.97Equal Weight$00.0000.00% ROILKFTLakefront Biotherapeutics American Depositary Shares1/23/2025Reiterated Rating$23.93Underweight$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
